April 29, 2020
Lysogene Reports Its Cash Position as of 31 March 2020
Cash and cash equivalent of €29.9 million1 as of 31 March 2020 PARIS–(BUSINESS WIRE)–Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS),…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Lysogene
October 17, 2019
Lysogene names Stéphane Durant des Aulnois as Chief Financial Officer
Lysogene has named Stéphane Durant des Aulnois, from Ipsen, as new Chief Financial Officar, who will also be a member…
September 30, 2019
Lysogene first half 2019 net loss €1.9 million
Lysogene posted net loss, for the first half of 2019 which amounted to €1.9 million compared to €7.2 million in the first half of 2018, with €6.8 million revenues in the first half 2019.
February 8, 2017
Lysogene raises €22.6 million, focuses on developing two drugs for deadly CNS diseases
French biotechnology company Lysogene has kicked off well with its initial public offering on Euronext Paris stock market by raising €22.6 million.